One test, four diseases: could this be the end of missed diagnoses?

NCT ID NCT07170748

Recruiting now Diagnosis Sponsor: MagIA Diagnostics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new device called MagIA H3S that can screen for HIV, hepatitis B, hepatitis C, and syphilis using a single blood sample. Researchers will enroll about 2,950 people in Ivory Coast and Kenya to see how accurate the device is compared to standard lab tests. If it works well, it could make widespread screening easier in areas with limited healthcare resources.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MagIA H3S diagnostic device
What this could lead to: If successful, this could provide a fast, affordable way to test for four major infections at once, improving early detection in remote areas.
What could go wrong: This is a performance evaluation, not a treatment trial. The device may not be as accurate as lab tests, and results may vary across populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HBV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection hepatitis C virus infection HIV infectious disease syphilis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HBV HCV HIV MULTIPLEX TESTING OF HIV, HBV, HCV AND SYPHILIS POINT OF CARE TESTING SYPHILIS

Contacts and locations

Locations

Centre de Diagnostic et de Recherche sur le SIDA et les autres Maladies Infectieuses - CHU Treichville
RECRUITING

Abidjan, Côte d’Ivoire
Kenya Medical Research Institute (KEMRI)
RECRUITING

Nairobi, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.